Multi-year project to advance knowledge of nasal mucosal immune response
A new initiative to better understand immune responses caused by mucosal vaccines is bringing together academia, the UK government and industry
New partnership to explore future applications of vaccines and beyond
French pharmaceutical company Sanofi have joined Imperial Business Partners (IBP), Imperial’s corporate membership programme.
Plant-based vaccines could expand access across Africa
Plant-based vaccines could help expand access across Africa according to a new Imperial report.
Personalising risk from COVID-19 key to protecting immunosuppressed people
New research underscores the need for ongoing COVID-19 protection for people with weakened immune systems.
New study to look at how people develop resistance to flu
An international project into flu immunity could help develop better medications and vaccines to prevent severe disease.
Imperial students tackle vaccine hesitancy during the Hackathon
Students harnessed Fetch.ai’s agents technology to address vaccine hesitancy during a two-day Hackathon at I-X.
Pandemic preparedness cannot rely on vaccine development alone
Vaccine experts drew attention to disruption factors around vaccine development and key action plans for future pandemic preparedness planning.
Feature
Event summary: Clinician-scientist-engineer challenges workshop in infection
Leading infection experts came together to explore clinical challenges in infection and how Imperial’s interdisciplinary expertise can solve them.
Future perspectives on mRNA technology in the UK
mRNA technology revolutionised our traditional approach to vaccine technology in the wake of COVID-19. But what next for the platform?
Vaccine Student Research Network Conference 2024
The Vaccine Student Research Network has recently hosted its inaugural conference at South Kensington campus.
